Back to top
more

Intuitive Surgical (ISRG)

(Real Time Quote from BATS)

$515.87 USD

515.87
330,848

+8.45 (1.67%)

Updated Nov 5, 2024 10:30 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Reasons to Hold on to Veeva Systems (VEEV) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Veeva Systems (VEEV) on its slew of partnerships and robust product adoptions.

Intuitive Surgical, Inc. (ISRG) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Intuitive Surgical, Inc. (ISRG) closed at $1,036.52 in the latest trading session, marking a -0.55% move from the prior day.

Here's Why You Should Retain Integra (IART) Stock for Now

by Zacks Equity Research

Solid performance across the CSS and Tissue Technologies segments is driving the top line for Integra (IART).

Thermo Fisher's (TMO) Oncomine Dx Gets CDx Approval for TIBSOVO

by Zacks Equity Research

Thermo Fisher (TMO) receives FDA go-ahead for the Oncomine Dx Target Test as a CDx for Servier's ivosidenib tablets, TIBSOVO.

SmileDirectClub (SDC) Reels Under Rising Costs, Debt Woes

by Zacks Equity Research

SmileDirectClub (SDC) sees net operating cash outflow in the second quarter.

BD (BDX) Veritor At-Home COVID-19 Test Receives EUA From FDA

by Zacks Equity Research

EUA for BD's (BDX) At-Home COVID-19 test is expected to boost home testing to prevent outbreaks and limit the rise in COVID-19 cases from the Delta variant.

Here's Why You Should Retain BD (BDX) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about BD (BDX) owing to its slew of product launches and regulatory approvals.

Here's Why You Should Invest In Tandem Diabetes (TNDM) Now

by Zacks Equity Research

Continued adoption of Tandem Diabetes' (TNDM) t:slim X2 technology and international expansion of the Control-IQ technology add to the company's solid second-quarter performance.

Has Intuitive Surgical (ISRG) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (ISRG) Outperforming Other Medical Stocks This Year?

Looking for Medical Stocks? The Zacks Rank Can Help You Find Winners

by Zacks Equity Research

The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.

Here's Why You Should Retain Masimo (MASI) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Masimo (MASI) owing to its slew of product launches and regulatory approvals.

Sweta Killa headshot

5 Stocks At the Forefront of the Latest S&P 500 Rally

by Sweta Killa

The S&P 500 showed strength to start the new week and hit a new peak on a vaccine boost. This benefited the KR, REGN, TJX, ISRG, MSFT stocks.

Here's Why You Should Retain PacBio (PACB) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about PacBio (PACB) owing to its slew of strategic deals and strength in its Sequel system.

Intuitive Surgical (ISRG) Hits 52-Week High: What's Behind It?

by Zacks Equity Research

Investors are optimistic about Intuitive Surgical's (ISRG) strength in its da Vinci surgical system.

Intuitive Surgical, Inc. (ISRG) Up 10% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Intuitive Surgical, Inc. (ISRG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Abiomed's (ABMD) Impella ECP Gets FDA's Breakthrough Device Tag

by Zacks Equity Research

Abiomed's (ABMD) Impella ECP is likely to offer critical hemodynamic support to a wider pool of coronary artery disease patients.

West Pharmaceutical (WST) Hits 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about West Pharmaceutical's (WST) robust proprietary products segment and its continued strength in R&D.

Masimo (MASI) Bridge Hailed as Opioid Substitute in New Study

by Zacks Equity Research

Masimo's (MASI) Bridge device is likely to allow more patients to be benefited by auriculotherapy, thereby reducing the possibility of opioid overuse.

Here's How Much a $1000 Investment in Intuitive Surgical, Inc. Made 10 Years Ago Would Be Worth Today

by Zacks Equity Research

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

ResMed (RMD) Hits New 52-Week High: What's Behind the Rally?

by Zacks Equity Research

Investors are optimistic about ResMed's (RMD) potential in digital health and its strong emphasis on product development.

Teleflex (TFX) Rides on UroLift Growth, Hurt by Pandemic Woes

by Zacks Equity Research

Teleflex (TFX) has decided to increase its investment in 2021 and run a national campaign for the full year.

Globus Medical (GMED) Gets FDA Nod for Excelsius3D

by Zacks Equity Research

The receipt of FDA's 510(k) clearance for Globus Medical's (GMED) Excelsius3D is expected to expand the company's presence in the intraoperative imaging system space.

3 Reasons to Add Catalent (CTLT) Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Catalent (CTLT) owing to its slew of strategic deals, and integrated development and product supply chain solutions.

BD's (BDX) New Offering to Boost Labs' Flow Cytometry Abilities

by Zacks Equity Research

BD's (BDX) latest product offering is expected to help improve access to instrumentation for complex scientific research to more laboratories.

Here's Why You Should Invest in Intuitive Surgical (ISRG) Now

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to gain traction from improving adoption of da Vinci Surgical System.